Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma
Emil Frei(Dana-Farber Cancer Institute), Alexandar Tzankov(University of Basel), Ken H. Young(Duke Medical Center), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Eric D. Hsi(Mayo Clinic), Ronald S. Go(Mayo Clinic), Michael Møller(Hospital South West Jutland), Zijun Y. Xu‐Monette(Duke University), Attilio Orazi(Texas Tech University), Carlo Visco(University of Verona), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), S Dirnhofer(University Hospital of Basel), J. Han van Krieken(Radboud University Nijmegen), Karen Dybkær(Aalborg University Hospital)
Cited by 30
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k